FDA Drug Recalls
1,463 recalls · Class I, newest first
Class I · High risk Terminated Dec 9, 2015
Reason Marketed without an approved NDA/ANDA: Product contains undeclared Sibutramine, Phenolphthalein and/or Diclofenac.
Class I · High risk Terminated Dec 3, 2015
Reason Marketed Without An Approved NDA/ANDA: Tainted product marketed as a dietary supplement. Product found to be tainted with sibutramine, an appetite…
Class I · High risk Terminated Nov 23, 2015
Reason Marketed without an approved NDA/ANDA - presence of undeclared sibutramine, desmethylsibutramine (an active metabolite of sibutramine) and/or…
Class I · High risk Terminated Oct 28, 2015
Reason Defective Delivery System; potential to have inaccurate dosage delivery
Class I · High risk Terminated Oct 28, 2015
Reason Defective Delivery System; potential to have inaccurate dosage delivery
Class I · High risk Terminated Oct 5, 2015
Reason Marketed Without an Approved NDA/ANDA: Product contains undeclared sibutramine.
Class I · High risk Terminated Oct 1, 2015
Reason Marketed without an Approved NDA/ANDA: Products contain undeclared active pharmaceutical ingredients; desmethyl carbondenafil and dapoxetine.
Class I · High risk Terminated Oct 1, 2015
Reason Marketed without an Approved NDA/ANDA: Products contain undeclared active pharmaceutical ingredients; desmethyl carbondenafil and dapoxetine.
Class I · High risk Terminated Sep 30, 2015
Reason Marketed without an Approved NDA/ANDA: Products contain undeclared active pharmaceutical ingredients; desmethyl carbondenafil and dapoxetine.
Class I · High risk Terminated Sep 30, 2015
Reason Marketed without an Approved NDA/ANDA: Products contain undeclared active pharmaceutical ingredients; desmethyl carbondenafil and dapoxetine.
Class I · High risk Terminated Sep 29, 2015
Reason Marketed Without An Approved NDA/ANDA: product marketed as a dietary supplement was found to be tainted with undeclared sibutramine, a previously…
Class I · High risk Terminated Sep 25, 2015
Reason Marketed without an Approved NDA/ANDA: Products contain undeclared desmethyl carbondenafil and dapoxetine.
Class I · High risk Terminated Sep 25, 2015
Reason Marketed without an Approved NDA/ANDA: Products contain undeclared desmethyl carbondenafil and dapoxetine.
Class I · High risk Terminated Sep 25, 2015
Reason Labeling: Label Error on Declared Strength- Bottles containing 500 mg acetaminophen tablets mislabeled to contain 325 mg tablets.
Class I · High risk Terminated Sep 25, 2015
Reason Labeling: Label Error on Declared Strength- Bottles containing 500 mg acetaminophen tablets mislabeled to contain 325 mg tablets.
Class I · High risk Terminated Sep 23, 2015
Reason Marketed without an approved NDA/ANDA: Product contains undeclared sibutramine and phenolphthalein.
Class I · High risk Terminated Sep 23, 2015
Reason Marketed without an approved NDA/ANDA: Product contains undeclared sibutramine and phenolphthalein.
Class I · High risk Terminated Sep 23, 2015
Reason Marketed without an approved NDA/ANDA: Product contains undeclared sibutramine and phenolphthalein.
Class I · High risk Terminated Aug 24, 2015
Reason Marketed Without an Approved NDA/ANDA: FDA sampling confirmed the presence of Salicylic acid in dietary supplements.
Class I · High risk Terminated Aug 24, 2015
Reason Marketed Without an Approved NDA/ANDA: FDA sampling confirmed the presence of Salicylic acid in dietary supplements.
Class I · High risk Terminated Aug 24, 2015
Reason Marketed Without an Approved NDA/ANDA: FDA sampling confirmed the presence of Salicylic acid in dietary supplements.
Class I · High risk Terminated Aug 24, 2015
Reason Marketed Without an Approved NDA/ANDA: FDA sampling confirmed the presence of Salicylic acid in dietary supplements.
Class I · High risk Terminated Aug 24, 2015
Reason Marketed Without an Approved NDA/ANDA: FDA sampling confirmed the presence of Salicylic acid in dietary supplements.
Class I · High risk Terminated Aug 24, 2015
Reason Marketed Without an Approved NDA/ANDA: FDA sampling confirmed the presence of Salicylic acid in dietary supplements.
Class I · High risk Terminated Aug 24, 2015
Reason Marketed Without an Approved NDA/ANDA: FDA sampling confirmed the presence of Salicylic acid in dietary supplements.